<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-EEO-1807</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-1807</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Влияние эритропоэтина на костномозговые мононуклеары</article-title><trans-title-group xml:lang="en"><trans-title>Effect of erythropoietin on bone marrow mononuclear cells</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4897-8676</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лыков</surname><given-names>А. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Lykov</surname><given-names>A. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лыков А.П. – к.м.н., ведущий научный сотрудник; старший научный сотрудник</p><p>630060, г. Новосибирск, ул. Тимакова, 2.</p></bio><bio xml:lang="en"><p>Lykov A.P., PhD (Medicine), Leading Research Associate; Senior Research Associate</p><p>630060, Novosibirsk, Timakova str., 2.</p></bio><email xlink:type="simple">aplykov2@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4752-988X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Суровцева</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Surovtseva</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Суровцева М.А. – к.м.н., старший научный сотрудник</p><p>630060, г. Новосибирск, ул. Тимакова, 2.</p></bio><bio xml:lang="en"><p>Surovtseva M.A., PhD (Medicine), Senior Research Associate</p><p>630060, Novosibirsk, Timakova str., 2.</p></bio><email xlink:type="simple">mfelde@ngs.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9956-0056</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Повещенко</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Poveshchenko</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Повещенко О.В. – д.м.н., заведующая лабораторией;</p><p>630060, г. Новосибирск, ул. Тимакова, 2.</p></bio><bio xml:lang="en"><p>Poveshchenko O.V., PhD, MD (Medicine), Head of Laboratory;</p><p>630060, Novosibirsk, Timakova str., 2.</p></bio><email xlink:type="simple">poveshchenkoov@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9818-8678</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чернявский</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Chernyavsky</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чернявский А.М. – д.м.н., руководитель</p><p>г. Новосибирск</p></bio><bio xml:lang="en"><p>Chernyavsky A.M., PhD, MD (Medicine), Head</p><p>Novosibirsk</p></bio><email xlink:type="simple">amchern@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8576-9617</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фомичев</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Fomichev</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Фомичев А.В. – к.м.н., научный сотрудник</p><p>г. Новосибирск</p></bio><bio xml:lang="en"><p>Fomichev A.V., PhD (Medicine), Research Associate</p><p>Novosibirsk</p></bio><email xlink:type="simple">a_fomichev@list.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8443-656X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бондаренко</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bondarenko</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бондаренко Н.А. – к.б.н., старший научный сотрудник</p><p>630060, г. Новосибирск, ул. Тимакова, 2.</p></bio><bio xml:lang="en"><p>Bondarenko N.A., PhD (Biology), Senior Research Associate</p><p>630060, Novosibirsk, Timakova str., 2.</p></bio><email xlink:type="simple">bond80288@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7380-2763</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ким</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kim</surname><given-names>I. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ким И.И. – к.м.н., научный сотрудник; младший научный сотрудник</p><p>630060, г. Новосибирск, ул. Тимакова, 2.</p></bio><bio xml:lang="en"><p>Kim I.I., PhD (Medicine), Research Associate; Junior Research Associate</p><p>630060, Novosibirsk, Timakova str., 2.</p></bio><email xlink:type="simple">kii5@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Научно-исследовательский институт клинической и экспериментальной лимфологии – филиал ФГБНУ «Федеральный исследовательский центр Институт цитологии и генетики Сибирского отделения Российской академии наук»;&#13;
ФГБУ «Национальный медицинский исследовательский центр имени академика Е.Н. Мешалкина» Министерства здравоохранения РФ<country>Россия</country></aff><aff xml:lang="en">Research Institute of Clinical and Experimental Lymphology, Branch of the Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences;&#13;
E. Meshalkin National Medical Research Center<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр имени академика Е.Н. Мешалкина» Министерства здравоохранения РФ<country>Россия</country></aff><aff xml:lang="en">E. Meshalkin National Medical Research Center<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>09</day><month>12</month><year>2019</year></pub-date><volume>22</volume><issue>1</issue><fpage>135</fpage><lpage>142</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лыков А.П., Суровцева М.А., Повещенко О.В., Чернявский А.М., Фомичев А.В., Бондаренко Н.А., Ким И.И., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Лыков А.П., Суровцева М.А., Повещенко О.В., Чернявский А.М., Фомичев А.В., Бондаренко Н.А., Ким И.И.</copyright-holder><copyright-holder xml:lang="en">Lykov A.P., Surovtseva M.A., Poveshchenko O.V., Chernyavsky A.M., Fomichev A.V., Bondarenko N.A., Kim I.I.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/1807">https://www.mimmun.ru/mimmun/article/view/1807</self-uri><abstract><p>Стволовые/прогениторные клетки, рассматриваемые как альтернативный способ терапии сердечной недостаточности, способствуют регенерации поврежденного миокарда при инфаркте миокарда. Эффективность клеточной терапии зависит от популяционного состава и функциональной активности клеточного трансплантата, а функциональная активность клеточного трансплантата, в свою очередь, зависит от условий микроокружения. Культивирование стволовых/прогениторных клеток с эритропоэтином стимулирует пролиферативный потенциал, устойчивость к гипоксии in vitro, а также стимулированию ангиогенеза in vivo. Проведено исследование влияния кратковременной инкубации костномозговых мононуклеаров (КМ-МНК) больных ишемической болезнью сердца (ИБС) с эритропоэтином на фенотип, клеточный цикл, апоптоз и пролиферативный потенциал. КМ-МНК выделяли из аспирата костного мозга больных ИБС на градиенте плотности, инкубировали в течение 60 минут с эритропоэтином (33,4 МЕ/мл). Методом проточной цитофлуориметрии показано, что в пуле КМ-МНК выявлены эндотелиальные прогениторные клетки, находящиеся на разных стадиях созревания и дифференцировки, мезенхимальные стволовые клетки, суммарное количество которых не превышает 30% от общего пула КМ-МНК. Кратковременная инкубация КМ-МНК с эритропоэтином снижает экспрессию «хоминг-рецептора» CD184 на CD34+ клетках и увеличивает экспрессию CD184 на CD31+ клетках в пуле КМ-МНК (p &lt; 0,05). Кроме этого, показано, что эритропоэтин задерживает CD34+ клетки в фазе покоя (G0G1), уменьшает долю клеток в фазе синтеза (S) и митоза (G2/M) (p &lt; 0,05) и не влияет на апоптоз по данным Annexin V-FITC Apoptosis Detection Kit. Эритропоэтин не оказывал существенного влияния на экспрессию КМ-МНК молекул, вовлеченных в обеспечение адгезии, таких как CD18, CD29, CD44, CD49a, CD54, CD62E, CD146 и CD202b. МТТ-методом показано, что кратковременная преинкубация КМ-МНК с эритропоэтином способствовала существенному снижению пролиферативной активности КМ-МНК (p &lt; 0,05), но отмечена тенденция повышения резистентности предобработанных эритропоэтином КМ-МНК к окислительному стрессу, индуцированному перекисью водорода. Выявлена сопряженность эндотелиальных прогениторных клеток, находящихся на разных стадиях созревания и дифференцировки, с количеством гемопоэтических стволовых клеток в общем пуле КМ-МНК. На количество CD34+/CD133+, CD34- /CD31+, CD45+/EpoR+ и CD34+/EpoR+ в пуле КМ-МНК влияет возраст больных. Таким образом, кратковременная инкубация КМ-МНК с эритропоэтином способствует задержке клеток в фазе покоя клеточного цикла, что, в свою очередь, способствует снижению пролиферативного потенциала КМ-МНК.</p></abstract><trans-abstract xml:lang="en"><p>Stem/progenitor cells are considered an alternative method of heart failure therapy by promoting regeneration of damaged myocardium in myocardial infarction. Effectiveness of cell therapy depends on the population composition and functional activity of the cell graft, and, in turn, it depends on the conditions of microenvironment. Cultivation of stem/progenitor cells with erythropoietin stimulates proliferative potential causing in vitro resistance to hypoxia, and in vivo stimulation of angiogenesis. We aimed for assessing effects of erythropoietin upon hematopoietic cells. We studied some effects of short-term incubation of bone marrow mononuclear cells (BM-MNCs) in patients with coronary heart disease (CHD) with erythropoietin upon cellular phenotype, cell cycle, apoptosis and their proliferative potential. BM-MNCs were isolated from bone marrow aspirate from patients with CHD in a density gradient, then incubated for 60 minutes with erythropoietin (33.4 IU/ml). Using flow cytometric assay of the total BM-MNCs pool, we have shown there endothelial progenitor cells at different stages of maturation and differentiation, mesenchymal stem cells are. Their total number did not exceed 30%. Short-term incubation of BM-MNCs with erythropoietin reduces expression of CD184 “homing receptor” molecules on CD34+ cells, and causes increase of CD184 on CD31+ cells in the BM-MNCs pool (p &amp;lt; 0.05). In addition, erythropoietin has been shown to cause a delay of CD34+ cells in the resting phase (G0G1), reduce a proportion of cells in the synthetic phase (S) and mitosis (G2/M) (p&amp;lt;0.05), and does not affect apoptosis, as shown by Annexin V-FITC Apoptosis Detection Kit. Erythropoietin had no significant effects on expression on BM-MNCs surface molecules involved in providing adhesion, such as CD18, CD29, CD44, CD49a, CD54, CD62E, CD146, and CD202b. MTT-method has shown that the short-term preincubation of BM-MNCs with erythropoietin contributed to a significant decrease in proliferative activity of BM-MNCs (p &amp;lt; 0.05). However, there was a tendency towards increased resistance of erythropoietin-pretreated BM-MNCs to oxidative stress induced by hydrogen peroxide. We have also revealed a correlation between the numbers of endothelial progenitor cells at different stages of differentiation, and numbers of hematopoietic stem cells in the total BM-MNCs pool. The number of CD34+/CD133+, CD34- / CD31+, CD45+/EpoR+, and CD34+/EpoR+ in BM-MNCs pool are dependent on the age of patients. Hence, a short-term incubation of BM-MNCs with erythropoietin promotes the cells to be retained in resting phase of the cell cycle, thus, in turn, helping to reduce proliferative potential of BM-MNCs.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>эритропоэтин</kwd><kwd>костномозговые мононуклеары</kwd><kwd>фенотип</kwd><kwd>клеточный цикл</kwd><kwd>апоптоз</kwd><kwd>пролиферация</kwd></kwd-group><kwd-group xml:lang="en"><kwd>erythropoietin</kwd><kwd>bone marrow</kwd><kwd>mononuclear cells</kwd><kwd>phenotype</kwd><kwd>cell cycle</kwd><kwd>apoptosis</kwd><kwd>proliferation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Захаров Ю.М. Цитопротекторные функции эритропоэтина // Клиническая нефрология. 2009. № 1. С. 16-21. [Zakharov Yu.M. Citoprotective effects of erythropoietin. Klinicheskaya nefrologiya = Clinical Nephrology, 2009, no. 1, pp. 16-21. (In Russ.)]</mixed-citation><mixed-citation xml:lang="en">Zakharov Yu.M. Citoprotective effects of erythropoietin. Klinicheskaya nefrologiya = Clinical Nephrology, 2009, no. 1, pp. 16-21. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Лыков А.П., Бондаренко Н.А., Сахно Л.В., Шевела Е.Я., Повещенко О.В., Ким И.И., Никонорова Ю.В., Коненков В.И. Влияние секреторных факторов эндотелиальных клеток на пролиферативную и миграционную способность мультипотентных мезенхимальных стромальных клеток человека // Фундаментальные исследования, 2014. № 4, ч. 2. С. 36-42. [Lykov A.P., Bondarenko N.A., Sakhno L.V., Shevela E.Ya., Poveschenko O.V., Kim I.I., Nikonorova Yu.V., Konenkov V.I. The impact of secretory factors endothelial cells on the functional activity of human multipotent mesenchymal stromal cells. Fundamentalnye issledovaniya = Fundamental Research, 2014, no. 4, Pt 2, pp. 36-42. (In Russ.)]</mixed-citation><mixed-citation xml:lang="en">Lykov A.P., Bondarenko N.A., Sakhno L.V., Shevela E.Ya., Poveschenko O.V., Kim I.I., Nikonorova Yu.V., Konenkov V.I. The impact of secretory factors endothelial cells on the functional activity of human multipotent mesenchymal stromal cells. Fundamentalnye issledovaniya = Fundamental Research, 2014, no. 4, Pt 2, pp. 36-42. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Лыков А.П., Никонорова Ю.В., Бондаренко Н.А., Повещенко О.В., Ким И.И., Повещенко А.Ф., Коненков В.И. Изучение пролиферации, миграции и продукции оксида азота костномозговыми мультипотентными мезенхимными стромальными клетками крыс Вистар при гипоксии и гипергликемии // Бюллетень экспериментальной биологии и медицины, 2015. Т. 159, № 4. С. 432-434. [Lykov A.P., Nikonorova Yu.V., Bondarenko N.A., Poveshchenko O.V., Kim I.I., Poveshchenko A.F., Konenkov V.I. Proliferation, migration, and production of nitric oxide by bone marrow multipotent mesenchymal stromal cells from Wistar rats in hypoxia and hyperglycemia. Byulleten eksperimentalnoy biologii i meditsiny = Bulletin of Experimental Biology and Medicine, 2015, Vol. 159, no. 4, pp. 432-434. (In Russ.)]</mixed-citation><mixed-citation xml:lang="en">Lykov A.P., Nikonorova Yu.V., Bondarenko N.A., Poveshchenko O.V., Kim I.I., Poveshchenko A.F., Konenkov V.I. Proliferation, migration, and production of nitric oxide by bone marrow multipotent mesenchymal stromal cells from Wistar rats in hypoxia and hyperglycemia. Byulleten eksperimentalnoy biologii i meditsiny = Bulletin of Experimental Biology and Medicine, 2015, Vol. 159, no. 4, pp. 432-434. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Осиков М.В., Ахматов В.Ю., Телешева Л.Ф., Федосов А.А., Агеев Ю.И., Суровяткина Л.Г. Плейотропные эффекты эритропоэтина при хронической почечной недостаточности // Фундаментальные исследования, 2013. № 7, ч. 1. С. 218-224. [Osikov M.V., Akhmatov V.Yu., Telesheva L.F., Fedosov A.A., Ageev Yu.I., Surovyatkina L.G. Pleiotropic effects of erythropoietin in chronic renal failure. Fundamentalnye issledovaniya = Fundamental Research, 2013, no. 7, Pt 1, pp. 218-224. (In Russ.)]</mixed-citation><mixed-citation xml:lang="en">Osikov M.V., Akhmatov V.Yu., Telesheva L.F., Fedosov A.A., Ageev Yu.I., Surovyatkina L.G. Pleiotropic effects of erythropoietin in chronic renal failure. Fundamentalnye issledovaniya = Fundamental Research, 2013, no. 7, Pt 1, pp. 218-224. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Bennis Y., Sarlon-Bartoli G., Guillet B., Lucas L., Pellegrini L., Velly L., Blot-Chabaud M., Dignat-Georges F., Sabatier F., Pisano P. Priming of late endothelial progenitor cells with erythropoietin before transplantation requires the CD131 receptor subunit and enhances their angiogenic potential. J. Thromb. Haemost. 2012, Vol. 10, no. 9, pp. 1914-1928.</mixed-citation><mixed-citation xml:lang="en">Bennis Y., Sarlon-Bartoli G., Guillet B., Lucas L., Pellegrini L., Velly L., Blot-Chabaud M., Dignat-Georges F., Sabatier F., Pisano P. Priming of late endothelial progenitor cells with erythropoietin before transplantation requires the CD131 receptor subunit and enhances their angiogenic potential. J. Thromb. Haemost. 2012, Vol. 10, no. 9, pp. 1914-1928.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hristov M., Zernecke A., Bidzhekov K., Liehn E.A., Shagdarsuren E., Ludwig A., Weber C. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ. Res., 2007, Vol. 100, no. 4, pp. 590-597.</mixed-citation><mixed-citation xml:lang="en">Hristov M., Zernecke A., Bidzhekov K., Liehn E.A., Shagdarsuren E., Ludwig A., Weber C. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ. Res., 2007, Vol. 100, no. 4, pp. 590-597.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hu R., Cheng Y., Jing H., Wu H. Erythropoietin promotes the protective properties of transplanted endothelial progenitor cells against acute lung injury via PI3K/Akt pathway. Shock, 2014, Vol. 42, no. 4, pp. 327-336.</mixed-citation><mixed-citation xml:lang="en">Hu R., Cheng Y., Jing H., Wu H. Erythropoietin promotes the protective properties of transplanted endothelial progenitor cells against acute lung injury via PI3K/Akt pathway. Shock, 2014, Vol. 42, no. 4, pp. 327-336.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Jang W.Y., Kim H.J., Li H., Jo K.D., Lee M.K., Yang H.O. The neuroprotective effect of erythropoietin on rotenone-induced neurotoxicity in SH-SY5Y cells through the induction of autophagy. Mol. Neurobiol., 2016, Vol. 53, pp. 3812-3821.</mixed-citation><mixed-citation xml:lang="en">Jang W.Y., Kim H.J., Li H., Jo K.D., Lee M.K., Yang H.O. The neuroprotective effect of erythropoietin on rotenone-induced neurotoxicity in SH-SY5Y cells through the induction of autophagy. Mol. Neurobiol., 2016, Vol. 53, pp. 3812-3821.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kahraman S., Yilmaz R., Kirkpantur A., Genctoy G., Arici M., Altun B., Erdem Y., Yasavul U., Turgan C. Impact of rHuEPO therapy initiation on soluble adhesion molecule levels in haemodialysis patients. Nephrology (Carlton), 2005, Vol. 10, no. 3, pp. 264-269.</mixed-citation><mixed-citation xml:lang="en">Kahraman S., Yilmaz R., Kirkpantur A., Genctoy G., Arici M., Altun B., Erdem Y., Yasavul U., Turgan C. Impact of rHuEPO therapy initiation on soluble adhesion molecule levels in haemodialysis patients. Nephrology (Carlton), 2005, Vol. 10, no. 3, pp. 264-269.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kamianowska M., Szczepanski M., Skrzydlewska E. Effects of erythropoietin on ICAM-1 and PECAM-1 expressions on human umbilical vein endothelial cells subjected to oxidative stress. Cell Biochem. Funct., 2011, Vol. 29, no. 6, pp. 437-441.</mixed-citation><mixed-citation xml:lang="en">Kamianowska M., Szczepanski M., Skrzydlewska E. Effects of erythropoietin on ICAM-1 and PECAM-1 expressions on human umbilical vein endothelial cells subjected to oxidative stress. Cell Biochem. Funct., 2011, Vol. 29, no. 6, pp. 437-441.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kandala J., Upadhyay G.A., Pokushalov E., Wu S., Drachman D.E., Singh J.P. Meta-analysis of stem cell therapy in chronic ischemic cardiomyopathy. Am. J. Cardiol., 2013, Vol. 112, no. 2, pp. 217-225.</mixed-citation><mixed-citation xml:lang="en">Kandala J., Upadhyay G.A., Pokushalov E., Wu S., Drachman D.E., Singh J.P. Meta-analysis of stem cell therapy in chronic ischemic cardiomyopathy. Am. J. Cardiol., 2013, Vol. 112, no. 2, pp. 217-225.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kang J., Yun J.Y., Hur J., Kang J.A., Choi J.I., Ko S.B., Lee J., Kim J.Y., Hwang I.C., Park Y.B., Kim H.S. Erythropoietin priming improves the vasculogenic potential of G-CSF mobilized human peripheral blood mononuclear cells. Cardiovasc. Res., 2014, Vol. 104, no. 1, pp. 171-182.</mixed-citation><mixed-citation xml:lang="en">Kang J., Yun J.Y., Hur J., Kang J.A., Choi J.I., Ko S.B., Lee J., Kim J.Y., Hwang I.C., Park Y.B., Kim H.S. Erythropoietin priming improves the vasculogenic potential of G-CSF mobilized human peripheral blood mononuclear cells. Cardiovasc. Res., 2014, Vol. 104, no. 1, pp. 171-182.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lykov A.P., Poveshchenko O.V., Cherniavsky A.M., Fomichev A.V., Surovtseva M.A., Bondarenko N.A., Kim I.I., Kareva Y.E., Tarkova A.R. Phenotype of bone marrow mononuclear cells before and after short-time precondition with Erythropoietin from patients with ischemic heart failure. Russian Open Medical Journal, 2018, Vol. 7, no. 2, pp. 202-208.</mixed-citation><mixed-citation xml:lang="en">Lykov A.P., Poveshchenko O.V., Cherniavsky A.M., Fomichev A.V., Surovtseva M.A., Bondarenko N.A., Kim I.I., Kareva Y.E., Tarkova A.R. Phenotype of bone marrow mononuclear cells before and after short-time precondition with Erythropoietin from patients with ischemic heart failure. Russian Open Medical Journal, 2018, Vol. 7, no. 2, pp. 202-208.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Liu N.M., Tian J., Wang W.W., Han G.F., Cheng J., Huang J., Zhang J.Y. Effects of erythropoietin on mesenchymal stem cells function of differentiation and secretion cultured under acute kidney injury microenvironment. Zhonghua Yi Xue Za Zhi, 2012, Vol. 92, no. 6, pp. 417-421.</mixed-citation><mixed-citation xml:lang="en">Liu N.M., Tian J., Wang W.W., Han G.F., Cheng J., Huang J., Zhang J.Y. Effects of erythropoietin on mesenchymal stem cells function of differentiation and secretion cultured under acute kidney injury microenvironment. Zhonghua Yi Xue Za Zhi, 2012, Vol. 92, no. 6, pp. 417-421.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Madigan M., Atoui R. Therapeutic use of stem cells for myocardial infarction. Bioengineering (Basel), 2018, Vol. 5, no. 2, E28. doi: 10.3390/bioengineering5020028.</mixed-citation><mixed-citation xml:lang="en">Madigan M., Atoui R. Therapeutic use of stem cells for myocardial infarction. Bioengineering (Basel), 2018, Vol. 5, no. 2, E28. doi: 10.3390/bioengineering5020028.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Seurder D., Radrizzani M., Turchetto L., Lo Cicero V., Soncin S., Muzzarelli S., Auricchio A., Moccetti T. Combined delivery of bone marrow-derived mononuclear cells in chronic ischemic heart disease: rationale and study design. Clin. Cardiol., 2013, Vol. 36, no. 8, pp. 435-441.</mixed-citation><mixed-citation xml:lang="en">Seurder D., Radrizzani M., Turchetto L., Lo Cicero V., Soncin S., Muzzarelli S., Auricchio A., Moccetti T. Combined delivery of bone marrow-derived mononuclear cells in chronic ischemic heart disease: rationale and study design. Clin. Cardiol., 2013, Vol. 36, no. 8, pp. 435-441.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Mohler E.R. 3rd, Lifeng Zhang, Medenilla E., Rogers W., French B., Bantly A., Moore J.S., Yonghong Huan, Murashima M., Berns J.S. Effect of darbepoetin alfa on endothelial progenitor cells and vascular reactivity in chronic kidney disease. Vasc. Med., 2011, Vol. 16, no. 3, pp. 183-189.</mixed-citation><mixed-citation xml:lang="en">Mohler E.R. 3rd, Lifeng Zhang, Medenilla E., Rogers W., French B., Bantly A., Moore J.S., Yonghong Huan, Murashima M., Berns J.S. Effect of darbepoetin alfa on endothelial progenitor cells and vascular reactivity in chronic kidney disease. Vasc. Med., 2011, Vol. 16, no. 3, pp. 183-189.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Tse H.F., Siu C.W., Zhu S.G., Songyan L., Zhang Q.Y., Lai W.H., Kwong Y.L., Nicholls J., Lau C.P. Paracrine effects of direct intramyocardial implantation of bone marrow derived cells to enhance neovascularization in chronic ischaemic myocardium. Eur. J. Heart Failure, 2007, Vol. 9, pp. 747-753.</mixed-citation><mixed-citation xml:lang="en">Tse H.F., Siu C.W., Zhu S.G., Songyan L., Zhang Q.Y., Lai W.H., Kwong Y.L., Nicholls J., Lau C.P. Paracrine effects of direct intramyocardial implantation of bone marrow derived cells to enhance neovascularization in chronic ischaemic myocardium. Eur. J. Heart Failure, 2007, Vol. 9, pp. 747-753.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Q.R., Wang B.H., Zhu W.B., Huang Y.H., Li Y., Yan Q. An in vitro study of differentiation of hematopoietic cells to endothelial cells. Bone Marrow Res., 2011, Vol. 2011, 846096. doi: 10.1155/2011/846096.</mixed-citation><mixed-citation xml:lang="en">Wang Q.R., Wang B.H., Zhu W.B., Huang Y.H., Li Y., Yan Q. An in vitro study of differentiation of hematopoietic cells to endothelial cells. Bone Marrow Res., 2011, Vol. 2011, 846096. doi: 10.1155/2011/846096.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
